Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

507 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Pichert G, Van t'veer L, Tung N, Weitzel JN, Couch FJ, Rubinstein WS, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Schildkraut J, Blum JL, Rebbeck TR. Domchek SM, et al. Among authors: olopade oi. JAMA. 2010 Sep 1;304(9):967-75. doi: 10.1001/jama.2010.1237. JAMA. 2010. PMID: 20810374 Free PMC article.
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL; Prevention and Observation of Surgical End Points Study Group. Rebbeck TR, et al. Among authors: olopade oi. N Engl J Med. 2002 May 23;346(21):1616-22. doi: 10.1056/NEJMoa012158. Epub 2002 May 20. N Engl J Med. 2002. PMID: 12023993 Free article.
Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.
Euhus DM, Smith KC, Robinson L, Stucky A, Olopade OI, Cummings S, Garber JE, Chittenden A, Mills GB, Rieger P, Esserman L, Crawford B, Hughes KS, Roche CA, Ganz PA, Seldon J, Fabian CJ, Klemp J, Tomlinson G. Euhus DM, et al. Among authors: olopade oi. J Natl Cancer Inst. 2002 Jun 5;94(11):844-51. doi: 10.1093/jnci/94.11.844. J Natl Cancer Inst. 2002. PMID: 12048272
MYC is amplified in BRCA1-associated breast cancers.
Grushko TA, Dignam JJ, Das S, Blackwood AM, Perou CM, Ridderstråle KK, Anderson KN, Wei MJ, Adams AJ, Hagos FG, Sveen L, Lynch HT, Weber BL, Olopade OI. Grushko TA, et al. Among authors: olopade oi. Clin Cancer Res. 2004 Jan 15;10(2):499-507. doi: 10.1158/1078-0432.ccr-0976-03. Clin Cancer Res. 2004. PMID: 14760071
Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, Olopade OI, Eisen A, Weber B, McLennan J, Sun P, Foulkes WD, Narod SA. Metcalfe K, et al. Among authors: olopade oi. J Clin Oncol. 2004 Jun 15;22(12):2328-35. doi: 10.1200/JCO.2004.04.033. J Clin Oncol. 2004. PMID: 15197194
Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Kotsopoulos J, Lubinski J, Lynch HT, Neuhausen SL, Ghadirian P, Isaacs C, Weber B, Kim-Sing C, Foulkes WD, Gershoni-Baruch R, Ainsworth P, Friedman E, Daly M, Garber JE, Karlan B, Olopade OI, Tung N, Saal HM, Eisen A, Osborne M, Olsson H, Gilchrist D, Sun P, Narod SA. Kotsopoulos J, et al. Among authors: olopade oi. Cancer Causes Control. 2005 Aug;16(6):667-74. doi: 10.1007/s10552-005-1724-1. Cancer Causes Control. 2005. PMID: 16049805
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, van 't Veer L, Eeles R, Evans DG, Tomlinson G, Matloff E, Narod SA, Eisen A, Domchek S, Armstrong K, Weber BL; PROSE Study Group. Rebbeck TR, et al. Among authors: olopade oi. J Clin Oncol. 2005 Nov 1;23(31):7804-10. doi: 10.1200/JCO.2004.00.8151. Epub 2005 Oct 11. J Clin Oncol. 2005. PMID: 16219936
507 results